» Articles » PMID: 10742110

The SH2 Tyrosine Phosphatase Shp2 is Required for Mammalian Limb Development

Overview
Journal Nat Genet
Specialty Genetics
Date 2000 Mar 31
PMID 10742110
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The tyrosine phosphatase Shp2 is recruited into tyrosine-kinase signalling pathways through binding of its two amino-terminal SH2 domains to specific phosphotyrosine motifs, concurrent with its re-localization and stimulation of phosphatase activity. Shp2 can potentiate signalling through the MAP-kinase pathway and is required during early mouse development for gastrulation. Chimaeric analysis can identify, by study of phenotypically normal embryos, tissues that tolerate mutant cells (and therefore do not require the mutated gene) or lack mutant cells (and presumably require the mutated gene during their developmental history). We therefore generated chimaeric mouse embryos to explore the cellular requirements for Shp2. This analysis revealed an obligatory role for Shp2 during outgrowth of the limb. Shp2 is specifically required in mesenchyme cells of the progress zone (PZ), directly beneath the distal ectoderm of the limb bud. Comparison of Ptpn11 (encoding Shp2)-mutant and Fgfr1 (encoding fibroblast growth factor receptor-1)-mutant chimaeric limbs indicated that in both cases mutant cells fail to contribute to the PZ of phenotypically normal chimaeras, leading to the hypothesis that a signal transduction pathway, initiated by Fgfr1 and acting through Shp2, is essential within PZ cells. Rather than integrating proliferative signals, Shp2 probably exerts its effects on limb development by influencing cell shape, movement or adhesion. Furthermore, the branchial arches, which also use Fgfs during bud outgrowth, similarly require Shp2. Thus, Shp2 regulates phosphotyrosine-signalling events during the complex ectodermal-mesenchymal interactions that regulate mammalian budding morphogenesis.

Citing Articles

Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma.

Zeng M, Liu C, Gong H, Tang Z, Wen J, Wang S Front Mol Biosci. 2024; 11:1367331.

PMID: 38596618 PMC: 11002252. DOI: 10.3389/fmolb.2024.1367331.


Thy-1 (CD90)-regulated cell adhesion and migration of mesenchymal cells: insights into adhesomes, mechanical forces, and signaling pathways.

Valdivia A, Avalos A, Leyton L Front Cell Dev Biol. 2023; 11:1221306.

PMID: 38099295 PMC: 10720913. DOI: 10.3389/fcell.2023.1221306.


SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities.

Liu Y, Zhang W, Jang H, Nussinov R Cell Mol Life Sci. 2023; 81(1):5.

PMID: 38085330 PMC: 11072105. DOI: 10.1007/s00018-023-05052-8.


Setting sail: Maneuvering SHP2 activity and its effects in cancer.

Welsh C, Allen S, Madan L Adv Cancer Res. 2023; 160:17-60.

PMID: 37704288 PMC: 10500121. DOI: 10.1016/bs.acr.2023.03.003.


RASopathies and cardiac manifestations.

Hilal N, Chen Z, Chen M, Choudhury S Front Cardiovasc Med. 2023; 10:1176828.

PMID: 37529712 PMC: 10387527. DOI: 10.3389/fcvm.2023.1176828.